Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec SE has again stressed its view that patient-driven data are the future for innovation, most recently by inking an R&D pact with Centogene in Gaucher’s disease, two days after the German drug discovery and development company entered a new alliance with Novo Nordisk A/S in chronic kidney disease. Its chief science officer Cord Dohrmann told Scrip that more, similarly structured collaborations can be expected.

The mining and use of patient datasets “increasingly underpins” Evotec’s quest for developing precision medicine, the CSO said. “To achieve precision medicines, you really need to understand disease on a...